Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ETHAMOLIN vs SCLEROSOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ethamolin (ethanolamine oleate) is a sclerosing agent that causes irritation of the vascular endothelium, leading to thrombosis, inflammation, and fibrosis of the vein wall, resulting in obliteration of varicose veins or esophageal varices.
SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of blood vessels and causing inflammation, thrombosis, and fibrosis, leading to obliteration of the injected vein.
FDA-approved: Treatment of esophageal varices that have recently bled to prevent rebleeding.,Off-label: Sclerotherapy of varicose veins, treatment of hemorrhoids, management of vascular malformations.
Treatment of uncomplicated spider veins (telangiectasias) and reticular veins of the lower extremities,Treatment of small varicose veins
5% solution intravenously, 0.1-0.3 m L per injection site, maximum 5 m L per site, repeated at 5-7 day intervals if needed.
0.5-5 m L of 5% solution administered by intrapleural injection once daily for up to 3 days.
Terminal elimination half-life is approximately 5-6 hours in adults with normal renal function; may be prolonged in renal impairment.
60-90 minutes (clinical context: rapid elimination requires multiple daily dosing for maintenance of effect)
Ethanolamine oleate is metabolized in the liver via oxidation and conjugation; exact enzymes are not well characterized.
Sodium tetradecyl sulfate is a small molecule that is not significantly metabolized; it is eliminated primarily via renal excretion.
Primarily renal excretion of unchanged drug and metabolites; >90% eliminated in urine within 24 hours, with less than 5% in feces.
Primarily renal (80-90% unchanged), minimal biliary/fecal (5-10%)
Approximately 20-30% bound to plasma proteins, primarily albumin.
20-30% (primarily to albumin)
Volume of distribution is approximately 0.5-0.8 L/kg, indicating distribution into extracellular fluid.
0.3-0.5 L/kg (clinical meaning: moderate distribution, mainly in extracellular fluid)
Intravenous: 100%; intramuscular: approximately 90-95% due to first-pass metabolism.
Oral: 10-20% (first-pass effect); subcutaneous: 70-80%; intramuscular: 75-85%; intravenous: 100%
No dose adjustment required for renal impairment.
No specific dose adjustment required; use with caution in severe renal impairment.
Contraindicated in severe hepatic disease (Child-Pugh class C). Use with caution in Child-Pugh class A or B; no specific dose modification established.
No specific dose adjustment required for Child-Pugh A or B; avoid in Child-Pugh C due to risk of toxicity.
Not recommended for use in children due to lack of safety and efficacy data.
Not recommended for pediatric use due to lack of safety and efficacy data.
Use with caution; consider reduced dose due to increased risk of sclerotherapy complications. No specific dose adjustments established.
No specific dose adjustment; monitor for pleural irritation and systemic effects due to increased sensitivity.
None explicitly required by FDA; however, severe adverse effects including anaphylaxis, renal failure, and esophageal ulceration have been reported.
There is no FDA black box warning for SCLEROSOL.
Risk of anaphylaxis and hypersensitivity reactions; have emergency equipment available.,Risk of esophageal ulceration, stricture, or perforation when used for varices.,May cause hemolysis and hemoglobinuria; monitor renal function.,Use caution in patients with cardiopulmonary disease, as rapid injection may cause bradycardia or hypotension.
Anaphylactic shock and allergic reactions,Arterial injection causing tissue necrosis,Deep vein thrombosis and pulmonary embolism,Intra-arterial injection leading to severe ischemia,Risk of anaphylaxis in patients with multiple allergies
Known hypersensitivity to ethanolamine oleate or any component.,Active gastrointestinal bleeding (for elective sclerotherapy).,Severe hepatic impairment or portal hypertension with high risk of perforation.,Uncontrolled systemic infection.
Known hypersensitivity to sodium tetradecyl sulfate,Acute thromboembolic disease,Severe peripheral arterial disease,Incompetent perforating veins without treatment of underlying reflux,Uncontrolled systemic disease (e.g., diabetes, hyperthyroidism),Local infection at the injection site,Bedridden patients
No specific food interactions. Avoid oral intake immediately after procedure until gag reflex returns.
No known food interactions. Maintain adequate hydration. Avoid alcohol for 24 hours post-treatment to minimize vasodilation.
Pregnancy Category D. Positive evidence of human fetal risk: Ethamolin (ethanolamine oleate) is contraindicated in pregnant women due to known teratogenicity in animal studies and potential for fetal harm. No adequate, well-controlled studies in pregnant women.
FDA Pregnancy Category C. Sclerosol (talc) is not absorbed systemically when used intrapleurally; however, inadvertent intravenous administration or systemic absorption may occur. Animal reproduction studies have not been conducted. Inadvertent maternal exposure could theoretically cause fetal harm. Use only if clearly needed during pregnancy; avoid during first trimester if possible.
It is not known whether ethanolamine oleate is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio: Not available.
No data on excretion into breast milk. Talc is not absorbed systemically when used intrapleurally, but trace amounts may enter milk. Due to lack of studies, caution is advised. The milk-to-plasma ratio is unknown. Consider discontinuing breastfeeding or alternative agents.
No specific dosing adjustments are recommended for pregnancy; however, use is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered protein binding) may affect drug distribution, but no dose adjustment studies exist. Avoid use unless benefit clearly outweighs risk.
No pharmacokinetic changes expected as systemic absorption is negligible. Standard intrapleural dosing (e.g., 2-10 g in 50-250 m L saline) may be used, but consider gestation-related pleural space changes. No dose adjustment recommended, but use lowest effective dose to minimize complications.
Ethamolin (ethanolamine oleate) is a sclerosing agent used for esophageal varices. Administer via intravariceal injection; maximum dose per session is 20 m L. Monitor for anaphylaxis, chest pain, and esophageal ulceration. Do not use in patients with known hypersensitivity to ethanolamine or oleic acid.
SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent used for varicose veins and telangiectasias. Avoid extravasation; tissue necrosis may occur. Use caution in patients with thrombophlebitis or hypercoagulable states. Max dose per session: 10 m L of 3% solution. Contraindicated in pregnancy and known allergy to the drug.
This medication is injected into the veins in your esophagus to stop bleeding.,You may experience chest pain or difficulty swallowing after the procedure.,Avoid eating or drinking until the numbing medicine wears off to prevent choking.,Report any signs of allergic reaction, such as hives, difficulty breathing, or swelling.,Follow up with your doctor for repeat procedures as needed.
You may experience a burning sensation at the injection site that lasts a few minutes.,Avoid strenuous activity and prolonged standing for 24-48 hours after treatment.,Wear compression stockings as directed to improve outcomes and reduce side effects.,Report any signs of infection, severe pain, or leg swelling to your doctor immediately.,Multiple sessions may be needed for complete vein closure.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ETHAMOLIN vs SCLEROSOL, answered by our medical review team.
ETHAMOLIN is a Sclerosing Agent that works by Ethamolin (ethanolamine oleate) is a sclerosing agent that causes irritation of the vascular endothelium, leading to thrombosis, inflammation, and fibrosis of the vein wall, resulting in obliteration of varicose veins or esophageal varices.. SCLEROSOL is a Sclerosing Agent that works by SCLEROSOL (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of blood vessels and causing inflammation, thrombosis, and fibrosis, leading to obliteration of the injected vein.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ETHAMOLIN and SCLEROSOL depend on the specific clinical indication. These are both Sclerosing Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ETHAMOLIN is: 5% solution intravenously, 0.1-0.3 m L per injection site, maximum 5 m L per site, repeated at 5-7 day intervals if needed.. The standard adult dose of SCLEROSOL is: 0.5-5 m L of 5% solution administered by intrapleural injection once daily for up to 3 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ETHAMOLIN and SCLEROSOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ETHAMOLIN is classified as Category C. Pregnancy Category D. Positive evidence of human fetal risk: Ethamolin (ethanolamine oleate) is contraindicated in pregnant women due to known teratogenicity in animal studies and . SCLEROSOL is classified as Category C. FDA Pregnancy Category C. Sclerosol (talc) is not absorbed systemically when used intrapleurally; however, inadvertent intravenous administration or systemic absorption may occur. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.